Between 20 and 50 percent of patients with high-risk localized prostate cancer will develop biochemical resistance, but historically, no Level I evidence for treatment was available. That’s why the EMBARK study is the first phase 3 trial to develop Level I evidence looking at monotherapy T suppression versus monotherapy enzalutamide versus combination enzalutamide and leuprolide. Dive into the findings with Dr. Neal Shore, who presented the “Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study” session at the 2024 ASCO Genitourinary Cancers Symposium.